ALK and non-small cell lung carcinoma: Next-generation ALK-TKIs such as alectinib, ceritinib, and lorlatinib have shown antitumor activity in patients with ALK-positive NSCLC who were previously treated with a different ALK-TKI.34,35 In our study, two patients (one with CLTC-ALK and the other with CTNAA-ALK) who progressed on alectinib were treated with ceritinib.